Country

Clinical trials in Poland

Active obesity and GLP-1 studies with at least one location in Poland.

47active studies

28recruiting now

36countries represented

136largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, SemaglutideTreatment

Australia, Bulgaria59 locations

KaileraSponsor

Updated 2026-09-01 · NCT07284979See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowNot applicable

Shift Workers' Health Behavior Action Program Across Europe

Night Shift Work, Obesity & OverweightCondition

Combined Lifestyle InterventionTreatment

Germany, Netherlands5 locations

Wageningen UniversitySponsor

Updated 2026-08-20 · NCT07631767See eligibility →

Recruiting nowPhase 3

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Overweight, ObesityCondition

Semaglutide, PlaceboTreatment

Belgium, Bulgaria62 locations

Novo Nordisk A/SSponsor

Updated 2026-08-18 · NCT07770841See eligibility →

Recruiting nowPhase 3

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, Bulgaria81 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT07509307See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Czechia, Germany136 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743450See eligibility →

Recruiting nowPhase 3

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ASC30 tablets A1, PlaceboTreatment

Canada, Czechia120 locations

Ascletis Pharma (China) Co., LimitedSponsor

Updated 2026-08-14 · NCT07743463See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

UBT251, UBT251 PlaceboTreatment

Australia, Germany70 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07668388See eligibility →

Recruiting nowPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

NNC0662-0419, SemaglutideTreatment

Croatia, Hungary63 locations

Novo Nordisk A/SSponsor

Updated 2026-08-10 · NCT07415954See eligibility →

Recruiting nowPhase 3

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China80 locations

Novo Nordisk A/SSponsor

Updated 2026-07-13 · NCT07571005See eligibility →

Recruiting nowPhase 3

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Obesity, Knee Osteoarthritis (OA)Condition

NNC0487-0111, Placebo (matched to NNC0487-0111 )Treatment

Australia, Bulgaria82 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT07481630See eligibility →

Recruiting nowNot applicable

Genetic, Microbiological and Behavioral Factors in Obesity

Obesity & Overweight, ObesityCondition

genetic polymorphism, gut microbiomeTreatment

Poland2 locations

Jan Kochanowski UniversitySponsor

Updated 2026-06-16 · NCT07650149See eligibility →

Recruiting nowNot applicable

Supplementation With Sirtuin Activators in Women With Increased Body Weight

Obesity & OverweightCondition

Sirtuin activators, PlaceboTreatment

Poland1 locations

Poznan University of Life SciencesSponsor

Updated 2026-05-22 · NCT07245979See eligibility →

Recruiting nowNot applicable

The Bialystok Bariatric Surgery Study

Obesity, Diabetes MellitusCondition

Bariatric surgeryTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2026-04-14 · NCT04634591See eligibility →

Recruiting nowNot applicable

Assessment of Respiratory Dysfunction in Obesity and the Use of IMT.

Obesity & Overweight, InflammationCondition

inspiratory muscle training, placebo-IMTTreatment

Poland1 locations

Wroclaw University of Health and Sport SciencesSponsor

Updated 2026-04-14 · NCT07307417See eligibility →

Recruiting nowNot applicable

The Effect of Pharmacotherapy With GLP-1 and GIP/GLP-1 Analogs on Changes in Qualitative and Quantitative Parameters of the Diet as Well as Metabolic and Behavioral Parameters in Patients With Excess Body Weight

GLP-1, NutritionCondition

Intervention not listedTreatment

Poland1 locations

Medical University of WarsawSponsor

Updated 2025-12-08 · NCT07270497See eligibility →

Recruiting nowPhase 4

Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes

Coronary Artery Disease, PreDiabetesCondition

Semaglutide 14 MG [Rybelsus], Dapagliflozin (Forxiga)Treatment

Poland1 locations

National Institute of Cardiology, Warsaw, PolandSponsor

Updated 2025-11-28 · NCT07254572See eligibility →

Recruiting nowNot applicable

A Multicenter Study for Evaluating a Digital Support System in Childhood Obesity Treatment

Childhood Obesity, Adolescent ObesityCondition

Evira Care treatment, Standard Lifestyle CareTreatment

Italy, Norway5 locations

Karolinska InstitutetSponsor

Updated 2025-10-06 · NCT04917601See eligibility →

Recruiting nowNot applicable

Comparison of Nissen-Sleeve and Gastric Bypass for GERD in Obese Patients

Gastro Esophageal Reflux, Severe ObesityCondition

Nissen-Sleeve Gastrectomy (N-SG), Roux-en-Y Gastric Bypass (RYGB)Treatment

Poland1 locations

Jagiellonian UniversitySponsor

Updated 2025-09-05 · NCT07158008See eligibility →

Recruiting nowNot applicable

Better4All Personalized Intervention Pilot Study

Obesity PreventionCondition

BETTER4U Mobile App and Wearable Use (End-User Group), BETTER4U Intervention Platform Testing (Implementer Group)Treatment

Cyprus, France7 locations

Harokopio UniversitySponsor

Updated 2025-08-13 · NCT07120802See eligibility →

Recruiting nowNot applicable

Polish Registry of Diabetes (PolReD)

Diabetes, ObesityCondition

Observational study - registryTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2025-03-26 · NCT04657367See eligibility →

Recruiting nowNot applicable

Genetics of the Acute Response to Oral Semaglutide

PreDiabetes, Prediabetic StateCondition

Semaglutide PillTreatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2025-03-26 · NCT05340868See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Osteoarthritis in the Knee, ObesityCondition

KBP-336, PlaceboTreatment

Czechia, Denmark20 locations

KeyBioscience AGSponsor

Updated 2025-02-19 · NCT06833749See eligibility →

Recruiting nowNot applicable

Assessment of Pulmonary Function in Relation to the Anesthetic Used in Patients Undergoing Bariatric Surgery

Obesity and Obesity-related Medical ConditionsCondition

Different drug type for conduction of general anesthesiaTreatment

Poland1 locations

Medical University of GdanskSponsor

Updated 2025-01-06 · NCT06759623See eligibility →

Recruiting nowNot applicable

The Influence of the "washoku" Diet on the Gut Microbiota in Postmenopausal Women

MenopauseCondition

Washoku dietTreatment

Poland1 locations

Joanna BajerskaSponsor

Updated 2024-11-14 · NCT06673199See eligibility →

Opening soonNot applicable

GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry

Heart Failure With Preserved Ejection Fraction, ObesityCondition

GLP-1 / GIP receptor agonistTreatment

Poland1 locations

Miedziowe Centrum Zdrowia SASponsor

Updated 2026-08-26 · NCT07787936See eligibility →

Opening soonNot applicable

Algal Lutein Against Decline of Intellectual Nimbleness

Menopausal Syndrome, Cognitive DeclineCondition

Lutein, PlaceboTreatment

Poland1 locations

Poznan University of Life SciencesSponsor

Updated 2026-05-20 · NCT07600567See eligibility →

Opening soonNot applicable

Breastmilk and the Link to Overweight/Obesity and Maternal Diet in the Mother-breastmilk-child Triad

Body Weight, Obesity & OverweightCondition

Intervention not listedTreatment

Canada, Poland4 locations

Warsaw University of Life SciencesSponsor

Updated 2026-03-09 · NCT07457515See eligibility →

Opening soonNot applicable

Metabolic Obesity in Normal Weight (MONW): Diagnostic Markers Stud

Normal Weight Obesity, Metabolically Obese Normal WeightCondition

Intervention not listedTreatment

Poland1 locations

Pomeranian Medical University SzczecinSponsor

Updated 2026-01-23 · NCT07358533See eligibility →

Opening soonNot applicable

ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic SyndromeCondition

Intervention not listedTreatment

Poland1 locations

Jarosław DrobnikSponsor

Updated 2026-01-15 · NCT07336563See eligibility →

Opening soonNot applicable

Better4All Personalized Intervention

Obesity PreventionCondition

Personalized lifestyle recommendations based on artificial intelligence (AI) and polygenic risk scores (PRS), Standard care: lifestyle counselling, healthy eating leaflet, and hyocaloric diet targeting ≥5% weight loss in 6 months.Treatment

Cyprus, France7 locations

Harokopio UniversitySponsor

Updated 2025-05-30 · NCT06997510See eligibility →

Invitation onlyNot applicable

Videolaryngoscopes in the Morbidly Obese

Obesity Difficult Airway Airway ManagementCondition

Airway managementTreatment

Poland1 locations

Uniwersytet Radomski im. Kazimierza PułaskiegoSponsor

Updated 2026-08-26 · NCT07787468See eligibility →

Invitation onlyNot applicable

MRI Assessment of Body Composition in Bariatric Surgery

Obesity (BMI>30)Condition

MRITreatment

Poland1 locations

University of Warmia and Mazury in OlsztynSponsor

Updated 2026-07-17 · NCT07711925See eligibility →

Invitation onlyNot applicable

Chronic Abdominal Pain After Laparoscopic Sleeve Gastrectomy

Obesity, Chronic PainCondition

QuestionnaireTreatment

Poland1 locations

Medical University of WarsawSponsor

Updated 2025-01-31 · NCT06686875See eligibility →

Invitation onlyNot applicable

Białystok PLUS - Polish Longitudinal University Study

Cardiovascular Diseases, DiabetesCondition

Discovering novel risk factors.Treatment

Poland1 locations

Medical University of BialystokSponsor

Updated 2023-03-15 · NCT03197363See eligibility →

Active, not recruitingPhase 1, Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)Condition

ALN-4324, PlaceboTreatment

Argentina, Canada22 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-14 · NCT06845202See eligibility →

Active, not recruitingPhase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Obesity, OverweightCondition

RO7204239, RO7204239 Matching PlaceboTreatment

Poland, Spain35 locations

Hoffmann-La RocheSponsor

Updated 2026-08-11 · NCT06965413See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes MellitusCondition

RO7795081, SemaglutideTreatment

Hungary, Poland50 locations

Hoffmann-La RocheSponsor

Updated 2026-07-07 · NCT07112872See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

The Impact of Probiotics on Bariatric Treatment Outcomes

Obesity &Amp; OverweightCondition

Probiotic, DietTreatment

Poland1 locations

University of Warmia and Mazury in OlsztynSponsor

Updated 2025-12-02 · NCT07258732See eligibility →

Active, not recruitingNot applicable

Physical Activity, Posture and Body Composition in Ontogeny

Pediatric Obesity, Postural BalanceCondition

psychoprophylactic program aimed at normalizing body weight through medical training, psychoprophylactic program aimed at improving body postureTreatment

Poland1 locations

Wroclaw University of Health and Sport SciencesSponsor

Updated 2024-05-17 · NCT06419829See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.